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NEWCASTLE DISEASE VIRUS STRAIN AF -2240 HN GENE EXPRESSION 
IN APOPTOTIC HUMAN COLON CANCER CELL LINES (HT-29)  
By 
SAMIRA KHODAI 
MARCH 2009 
Chairman:  Professor Datin Khatijah Mohd. Yusoff, PhD 
Faculty:  Biotechnology and Biomolecular Sciences 
Newcastle disease virus (NDV) is the causative agent of the Newcastle disease (ND).  
The virus has been used as vaccines in veterinary medicine to protect poultry against 
pathogenic NDV strains which causes respiratory disease but NDV in humans has 
interesting anti-neoplastic and immune stimulating properties.  NDV can be 
oncolytic and activate host immune cells to produce cytokines and to become 
cytotoxic against tumour cells via unknown mechanism.  The recombinant 
haemagglutinin-neuraminidase (HN) protein was obtained from Malaysian 
viserotropic-velogenic NDV strain AF2240 through reverse transcription-polymerase 
chain reaction (RT-PCR) and cloned into the mammalian expression vector pEGFP-
N2.  The constructed recombinant plasmid which was named pEGFP-N2/HN was 
used to transform into Escherichia coli Top 10 for amplification.  The extracted 
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plasmid from E. coli Top 10 was then used for transfection and apoptosis studies.  
The constructed plasmid, pEGFP-N2/HN, was transfected into HT-29 (human colon 
cancer) cell line and HeLa (human cervical cancer) cell line for protein expression 
and apoptosis studies, the 3T3 (normal mouse fibroblast) cell line was selected as 
control cell lines.  At 72 h post-transfection, protein expression of constructed 
pEGFP-N2/HN was analysed using SDS-PAGE, Western Blot and fluorescence 
microscope.  It was shown that the recombinant HN gene was expressed in HT-29 
cell as well as HeLa cells and 3T3 cells.  The cytotoxic effects of NDV strain 
AF2240 was determined by MTT assay.  Results from MTT assay showed that 50% 
inhibitory concentration (IC50) value in HT-29 cells obtained by 384 HA titer unit 
after 24 h while this amount decrease to 80 HA titer unit in HeLa cells during the 
same period.  However after 48 h treatment IC50 in HT-29 cells obtained by 380 HA 
titer unit and in HeLa cells this amount decreased to 64 HA titer unit.  At 72 h 
treatment IC50 of HT-29 cells was obtained by 300 HA titer unit, in HeLa cells this 
amount was only 4 HA titer unit.  In 3T3 cells no inhibition effect was observed after 
infection with NDV strain AF2240.  The apoptosis effects of NDV strain AF2240 
infection and pEGFP-N2/HN expression on HT-29, HeLa and 3T3 cell were 
analysed by Flow cytometry in which Propidium Iodide was used for cell staining, 
the untreated cells were considered as control.  Infection studies were carried out 
with NDV strain AF2240 at its IC50 HA titer unit for 24, 48 and 72 h.  Transfection 
studies were performed with 4 μg of constructed plasmid, pEGFP-N2/HN, for 72 h.  
Flow cytometry results from pEGFP-N2/HN transfection studies showed the 
involvement of HN gene expression of NDV strain AF2240 in inducing apoptosis in 
tumour cells but not normal cells.  Flow cytometry result from transfection studies 
v 
showed that the apoptosis induction of pEGFP-N2/HN transfection in HeLa cells was 
higher than apoptosis induction in HT-29 cells.  Early apoptosis effect of NDV strain 
AF2240 infection and pEGFP-N2/HN transfection on HT-29, HeLa and 3T3 cell 
were analysed by Flow cytometry in which Annexin V staining was used, in all 
experiments untreated cells were considered as control.  The Flow cytometry results 
showed that NDV strain AF2240 infection was able to trigger early apoptosis in 
tumour cell line after 12 h while transfection of tumour cells with pEGFP-N2/HN 
induced early apoptosis after 24 h, no early apoptosis induction has been observed in 
normal cells.  In conclusions the recombinant HN gene of NDV strain AF2240 
expressed in human colon cancer cells (HT-29) and human cervical cancer cells 
(HeLa) as well as mouse normal fibroblast cells (3T3).  The expressed recombinant 
HN protein of NDV strain AF2240 induced apoptosis in human tumor cells (HT-29 
and HeLa) without any cytotoxic effects on normal fibroblast cells. 
vi 
Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia 
sebagai memenuhi keperluan untuk ijazah Master punya Sains 
VIRUS NEWCASTLE (BAKA/STRAIN AF-2240) EKSPRESI GEN HN 
KE DALAM SEL KANSER COLON APOPTOTIK MANUSIA (HT-29) 
Oleh 
SAMIRA KHODAI 
MARCH 2009 
Pengerusi:  Profesor Datin Khatijah Mohd. Yusoff, PhD 
Fakulti:  Biotechnologi dan Sains Biomolekul 
Penyakit Newcastle adalah disebabkan oleh virus jenis NDV (Newcastle Disease 
Virus).  NDV telah lama digunakan sebagai vaksin dalam perubatan vetrinari untuk 
melindungi ternakan daripada strain pathogeniknya yang merupakan penyebab 
penyakit respiratori.  Berbeza dalam manusia, virus tersebut menunjukan ciri-ciri 
anti-neoplastik dan juga sebagai peransang sistem imun.  Oleh itu, NDV mampu 
bertindak sebagai onkolitik lalu mengaktifkan sistem imun perumah untuk 
menghasilkan sitokinin yang kemudiannya bertukar menjadi sitotoksik terhadap sel-
sel tumor melalui suatu mekanisme yang tidak dikenali.  
Protein recombinan haemagglutinin-neuraminidase (HN) yang didapati daripada 
strain viserotropik-velogenik NDV Malaysia jenis AF2240 melalui reaksi rantai 
transkripsi polymerase berbalik (RT-PCR) diklonkan ke dalam vector ekspresi 
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mamalia pEGFP-N2.  Plasmid recombinan (pEGFP-N2/HN) yang terhasil 
diamplifikasikan dengan bantuan Escherichia coli Top 10.  Bagi tujuan transfeksi 
serta kajian apoptosis, pEGFP-N2/HN dipindahkan ke sel-sel HT-29 (kanser kolon 
manusia) dan sel-sel HeLa (kanser servikal manusia) di mana sel-sel 3T3 (fibroblast 
tikus normal) dijadikan sebagai kawalan. 
Selepas 72 jam, protein ekspresi daripada pEGFP-N2/HN dianalisis dengan SDS-
PAGE, Western Blot dan juga mikroskop fluorescene.  Keputusan bagi ketiga-tiga 
jenis sel mengesahkan kehadiran gen recombinan HN padanya.  Selain itu, sel-sel 
HT-29, HeLa and 3T3 juga dirawat dengan larutan NDV (strain AF2240) 512 HA 
unit titer bagi tempoh masa yang berlainan iaitu 24, 48 and 72 jam untuk mengetahui 
kadar sitotoksiknya juga dikenali sebagai ujian MTT assay.  Bagi tempoh masa 
24jam, IC50 (50% inhibitory concentration) bagi sel-sel HT-29 dan HeLa didapati 
384 dan 80 HA unit titer masing-masing.  Manakala bagi 48 jam pula bersamaan 
dengan 380 dan 64 HA unit yang kemudiannya menurun kepada 300 dan 4 HA unit 
titer masing-masing apabila mencecah 72 jam.  Pemerhatian menunjukan tiada kesan 
pada sel-sel 3T3 bagi ketiga-tiga tempoh masa berkenaan. 
Kesan apoptosis dianalisis menggunakan teknik flowsitometri dengan Propidium 
Iodide sebagai pewarna sel dimana sel-sel yang tidak diwarna dianggap sebagai 
kawalan.  Kajian berkaitan infeksi dijalankan dengan sel-sel yang telah dirawat 
dengan NDV (strain AF2240) pada nilai IC50 HA unit titer tertentu bagi tempoh masa 
24, 48 dan 72 jam.  Manakala transfeksi pula dikaji dengan 4µg plasmid recombinan 
pEGFP-N2/HN selama 72 jam. Keputusan flowsitometri daripada kajian transfeksi 
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menunjukan penglibatan gen ekspresi HN daripada NDV dalam mencetuskan proses 
apoptosis pada sel-sel tumor dan bukannya pada sel-sel normal.  Kadar induksi 
apoptosis terbukti lebih tinggi dalam sel-sel HeLa berbanding sel-sel HT-29.  Pada 
peringkat awal apoptosis, pewarna jenis Annexin V telah digunakan dalam 
flowsitometri terhadap ketiga-tiga jenis sel tersebut manakala sel-sel yang tidak 
diwarna sebagai kawalan.  Flowsitometri mengesahkan infeksi dengan NDV strain 
AF2240 mencetuskan apoptosis awal selepas 12 jam berbanding transfeksi dengan 
pEGFP-N2/HN yang mencetuskan apoptosis awal hanya selepas 24 jam.  Tiada 
sebarang kesan apoptosis awal pada sel-sel yang normal diperhatikan. 
Sebagai kesimpulannya, gen recombinan HN daripada NDV baka AF2240 telah di 
ekspresikan ke dalam sel-sel kanser kolon manusia (HT-29), sel-sel kanser servikal 
manusia (HeLa) dan juga pada sel-sel fibroblast tikus normal.  Ternyata gen tersebut 
dapat mencetuskan apoptosis pada sel-sel tumor manusia (HT-29 and HeLa) 
manakala tiada sebarang kesan sitotoksik terhadap sel-sel fibroblast normal. 
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CHAPTER 1 
INTRODUCTION 
Newcastle disease virus (NDV) contains a single-stranded, negative-sense, non-
segmented RNA genome and belongs to the genus Avulavirus in the family 
Paramyxoviridae (Mayo 2002 .a).  The genomic RNA is 15,186 nucleotides in length 
(Krishnamurthy and Samal, 1998) and contains six genes that encode at least seven 
proteins (Steward et al., 1993).  The envelope of NDV contains two glycoproteins, 
the hemagglutinin-neuraminidase (HN) and fusion (F) proteins: the HN protein 
mediates attachment of the virus to the cell, and the F protein mediates fusion of the 
viral envelope with cellular membranes (Scheid and Choppin 1974).  NDV is a 
paramyxovirus that causes Newcastle disease in a wide variety of birds (Seal et al., 
2000).  In humans NDV is generally not very virulent and causes only mild flu-like 
symptoms or conjunctivitis and/or laryngitis (Moss et al., 1996).  It has been labeled 
as a complementary and alternative medicine treatment because it is widely believed 
to be nontoxic for normal cells (Moss., et al., 1996).  The virus is able to raise host 
immune system against tumour and an innate capacity to stimulate the production of 
host cytokines that have potential anticancer activity (Beard and Hanson, 1984).  
NDV has been used in a clinical setting as an experimental oncolytic agent for more 
than 30 years (Csatary, 1971).  Naturally occurring NDV has been reported to be an 
effective oncolytic agent in a variety of animal tumor models (Sinkovics and 
Horvath, 2000).  It has been used in vaccination with tumor cell oncolysates in 
people with head and neck squamous cell carcinomas (Karcher et al., 2004) tumors 
of digestive tract (Liang et al., 2003) glioblastoma multiform (Schneider et al., 2001; 
Steiner et al., 2004) malignant melanoma (Cassel et al., 1988; Batliwalla et al., 1998; 
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Wallack et al., 1998) colorectal carcinoma (Ockert et al., 1996; Schlag et al., 1992) 
and other advanced cancers. 
The mechanisms governing cytotoxicity effects of NDV remains to be fully 
characterised.  Many NDV strains are known to evoke apoptosis in cancer cells 
through cell-to cell contact or stimulation of immune system (Washburn et al., 2003).  
The differences observed in tumour cell cytotoxicity might be a reflection of the 
differences in the major surface glycoproteins, it has been shown that NDV strains 
with differences only in the HN proteins will have different levels of cytotoxicity 
against tumour cells (Zeng et al., 2002).  The HN protein of NDV mediates apoptosis 
in NDV-infected cells.  Since NDV enter all types of cells using sialic acid 
receptors, the observed differences in cytotoxicity against tumour cells by these 
viruses are likely to be due to other HN protein functional differences that do not 
alter receptor specificity (Zeng and Schirrmacher, 2002).  It has been shown that the 
HN protein of the virus causes apoptosis in chicken embryo fibroblast cells 
(Ravindra et al., 2008).  Tumour cells expressing the HN protein demonstrated 
decreased DNA content, phosphatidylserine exposure and increased cytoplasmic 
vacuolation. Up-regulation of caspase-1, -9, -8, -3, loss of mitochondrial 
transmembrane potential and an increase in oxidative stress were also observed in 
cells expressing the HN protein.  Based on above data it can be concluded that HN 
protein of NDV potentially causes apoptosis in tumour cells. 
